173 related articles for article (PubMed ID: 31396344)
1. Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.
Lu S; Guo M; Fan Z; Chen Y; Shi X; Gu C; Yang Y
Am J Transl Res; 2019; 11(7):4397-4410. PubMed ID: 31396344
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
[TBL] [Abstract][Full Text] [Related]
3. KIF18B promotes breast cancer cell proliferation, migration and invasion by targeting TRIP13 and activating the Wnt/β-catenin signaling pathway.
Liu L; Zhang Z; Xia X; Lei J
Oncol Lett; 2022 Apr; 23(4):112. PubMed ID: 35251343
[TBL] [Abstract][Full Text] [Related]
4. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
[TBL] [Abstract][Full Text] [Related]
5. Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit.
Marks DH; Thomas R; Chin Y; Shah R; Khoo C; Benezra R
Cell Rep; 2017 May; 19(9):1832-1845. PubMed ID: 28564602
[TBL] [Abstract][Full Text] [Related]
6. Mode of interaction of TRIP13 AAA-ATPase with the Mad2-binding protein p31comet and with mitotic checkpoint complexes.
Miniowitz-Shemtov S; Eytan E; Kaisari S; Sitry-Shevah D; Hershko A
Proc Natl Acad Sci U S A; 2015 Sep; 112(37):11536-40. PubMed ID: 26324890
[TBL] [Abstract][Full Text] [Related]
7. TRIP13 Regulates Both the Activation and Inactivation of the Spindle-Assembly Checkpoint.
Ma HT; Poon RYC
Cell Rep; 2016 Feb; 14(5):1086-1099. PubMed ID: 26832417
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
[TBL] [Abstract][Full Text] [Related]
9. Insights into a Crucial Role of TRIP13 in Human Cancer.
Lu S; Qian J; Guo M; Gu C; Yang Y
Comput Struct Biotechnol J; 2019; 17():854-861. PubMed ID: 31321001
[TBL] [Abstract][Full Text] [Related]
10. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
Niu L; Gao Z; Cui Y; Yang X; Li H
Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
[TBL] [Abstract][Full Text] [Related]
11. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
Chang S; Xiao W; Xie Y; Xu Z; Li B; Wang G; Hu K; Zhang Y; Zhou J; Song D; Zhu H; Wu X; Lu Y; Shi J; Zhu W
Cancer Med; 2023 Dec; 12(23):21321-21334. PubMed ID: 37942576
[TBL] [Abstract][Full Text] [Related]
12. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
Zhou XY; Shu XM
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
[TBL] [Abstract][Full Text] [Related]
13. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
14. TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion.
Kurita K; Maeda M; Mansour MA; Kokuryo T; Uehara K; Yokoyama Y; Nagino M; Hamaguchi M; Senga T
Oncol Lett; 2016 Dec; 12(6):5240-5246. PubMed ID: 28105232
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways.
Lan J; Huang J; Tao X; Gao Y; Zhang L; Huang W; Luo J; Liu C; Deng Y; Liu L; Liu X
J Cell Mol Med; 2022 May; 26(9):2673-2685. PubMed ID: 35322916
[TBL] [Abstract][Full Text] [Related]
16. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
[TBL] [Abstract][Full Text] [Related]
17. TRIP13 Functions in the Establishment of the Spindle Assembly Checkpoint by Replenishing O-MAD2.
Ma HT; Poon RYC
Cell Rep; 2018 Feb; 22(6):1439-1450. PubMed ID: 29425500
[TBL] [Abstract][Full Text] [Related]
18. Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death.
Rios Garcia M; Meissburger B; Chan J; de Guia RM; Mattijssen F; Roessler S; Birkenfeld AL; Raschzok N; Riols F; Tokarz J; Giroud M; Gil Lozano M; Hartleben G; Nawroth P; Haid M; López M; Herzig S; Berriel Diaz M
Adv Sci (Weinh); 2022 Oct; 9(29):e2104291. PubMed ID: 36031387
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic role of TRIP13 in regulating proliferation, invasion, and cell cycle checkpoint in NSCLC cells.
Zhang Q; Dong Y; Hao S; Tong Y; Luo Q; Aerxiding P
Int J Clin Exp Pathol; 2019; 12(9):3357-3366. PubMed ID: 31934178
[TBL] [Abstract][Full Text] [Related]
20. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
